Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

BACKGROUND: Ustekinumab is currently approved globally in Crohn’s disease (CD) and psoriatic diseases. Recent phase 3 data demonstrate safety/efficacy in ulcerative colitis (UC). Crohn’s disease and UC phase 3 programs had similar study designs, facilitating integrated safety analyses. METHODS: Data...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, William J, Feagan, Brian G, Danese, Silvio, O’Brien, Christopher D, Ott, Elyssa, Marano, Colleen, Baker, Thomas, Zhou, Yiying, Volger, Sheri, Tikhonov, Ilia, Gasink, Christopher, Sands, Bruce E, Ghosh, Subrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205635/
https://www.ncbi.nlm.nih.gov/pubmed/32964215
http://dx.doi.org/10.1093/ibd/izaa236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205635/
https://www.ncbi.nlm.nih.gov/pubmed/32964215
http://dx.doi.org/10.1093/ibd/izaa236

Ejemplares similares